Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Tagatose is a low-calorie sweetener with a structure similar to fructose. Its use in supporting or treating Metabolic Syndrome is justified by emerging scientific evidence, though the strength of this evidence is moderate and further research is necessary. Several clinical studies and trials have evaluated tagatose's metabolic effects. Tagatose is known to have a minimal impact on blood glucose and insulin levels due to its low glycemic index, making it attractive for people with insulin resistance or at risk for type 2 diabetes—a component of Metabolic Syndrome.

Notably, a randomized, placebo-controlled study published in Diabetes, Obesity & Metabolism (2011) found that tagatose supplementation improved glycemic control in subjects with type 2 diabetes. Other studies suggest that tagatose can reduce postprandial glucose and insulin responses and may positively influence lipid profiles by lowering triglyceride levels. Animal studies have also shown that tagatose may reduce body weight and visceral fat accumulation, factors involved in Metabolic Syndrome.

However, the number of high-quality, large-scale human trials remains limited, and while results are promising, they do not yet establish tagatose as a mainstream therapy for Metabolic Syndrome. Side effects such as gastrointestinal discomfort have also been reported at higher doses. Thus, tagatose's use is scientifically supported, but the evidence is not yet strong enough for widespread medical adoption.

More about Tagatose
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Tagatose

Products containing Tagatose